Once-a-day stimulant is safe for ADHD, can be used after 1 year

Published Date: 13 Mar 2023

New research shows that once-daily speech-stimulating medications for the treatment of ADHD in people age 6 and older are safe and effective after one year of pain treatment.

Read Full News

Latest News

Anxiety and Depression May Raise Risk for Aneurysm Rupture

Anxiety and depression are linked to an increased risk for rupture and mortality in patients with unruptured intracranial aneurysms, a new cohort study shows.

China Approves Market Launch Of Brain-computer Interface Medical Device in World First

China's drug regulator said on Friday that it has given the nod for a brain-computer interface (BCI) system ⁠that helps restore hand-movement ability to be sold, the world's...

Why Aren’t Canadians Getting Enough Sleep?

The change to daylight saving time and the marking of World Sleep Day call attention to the factors that contribute to sleep deficits among Canadians.

Single IV Ketamine Promising for Depression in MCI

Ketamine is well-tolerated in older adults with both mild cognitive impairment and depression and associated with improved depression scores, a new study shows.

Late Complications Common After CVT, Even After Recovery

Although a majority of patients with cerebral venous sinus thrombosis achieve independence, 1 in 3 may develop delayed complications such as seizures, a study shows.

Activity Trackers May Predict MS Progression

Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.

Todays Updates

LAIs vs Oral Antipsychotics for Bipolar I Rehospitalization

Long-acting injectable antipsychotics are linked to lower rehospitalization rates than oral antipsychotics in patients with bipolar I disorder, a study shows.

MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Todays Updates

LAIs vs Oral Antipsychotics for Bipolar I Rehospitalization

Long-acting injectable antipsychotics are linked to lower rehospitalization rates than oral antipsychotics in patients with bipolar I disorder, a study shows.

MRI-Guided TULSA Speeds Recovery vs Robotic Prostatectomy

The CAPTAIN trial shows faster recovery, fewer complications, and better early function with the minimally invasive therapy in men with intermediate-risk prostate cancer.

Latest News

Anxiety and depression are linked to an increased risk for rupture and mortality in patients with unruptured intracranial aneurysms, a new cohort study shows.

China's drug regulator said on Friday that it has given the nod for a brain-computer interface (BCI) system ⁠that helps restore hand-movement ability to be sold, the world's...

The change to daylight saving time and the marking of World Sleep Day call attention to the factors that contribute to sleep deficits among Canadians.

Ketamine is well-tolerated in older adults with both mild cognitive impairment and depression and associated with improved depression scores, a new study shows.

Although a majority of patients with cerebral venous sinus thrombosis achieve independence, 1 in 3 may develop delayed complications such as seizures, a study shows.

Reduced daytime physical activity, as measured with wearable trackers, is tied to increased risk for multiple sclerosis progression and brain atrophy, new research shows.

News All Time

Fertility Treatments Linked to Higher Med Use in Offspring

Children conceived through medically assisted reproduction have higher out-of-hospital healthcare utilization including mental health medications.

Lifetime Risk Estimates for Dementia, MCI: New Data

Mild cognitive impairment before dementia is common in older adults, with women facing a higher lifetime burden and Black adults an earlier onset, new research shows.

Fibromyalgia-PTSD Link Shows Bidirectional Relationship

Research suggests a bidirectional relationship between posttraumatic stress disorder and fibromyalgia in military service members exposed to combat environments.

Trials Offer Mixed Results on BTK Potential for PPMS

Promising findings for fenebrutinib and disappointing results for tolebrutinib offer mixed results on the potential of BTK inhibitors for primary progressive MS.

Redefining Cognitive Assessment With One Blood Test

Blood p-tau217 testing in real-world practice enhances diagnostic accuracy and neurologists' diagnostic confidence, with the greatest diagnostic shifts seen in mild cognitive impairment and dementia.

What If We’ve Been Wrong About How ADHD Drugs Work?

A new analysis of brain scans from nearly 12,000 children could change the way clinicians and researchers think about how stimulants for ADHD work.

Wrist-Worn Sleep Trackers Predict Depression Relapse

Actigraphy data show irregular sleep-wake rhythms nearly double the risk for relapse in individuals with remitted major depressive disorder.

Japan Endorses IPS-derived Treatment for Parkinson's

A panel of specialists has endorsed an iPS cell-derived treatment for Parkinson's ⁠disease, paving the ‌way for the world's first medical products based on the technology.

Vertebral Fractures Tied to Lower Lung Volumes in ILD

Thoracic vertebral fractures may worsen lung function and reduce lung volumes in patients with interstitial lung disease.

Cognitive Training May Lower Dementia Risk 20 Years Later

In a long-running RCT, older adults who completed adaptive speed-of-processing training with boosters were less likely to develop dementia — a benefit not seen with memory or reasoning training.

Lifelong Cognitive Enrichment Tied to Lower Dementia Risk

Lifelong cognitive enrichment is linked to a lower risk for Alzheimer's disease, delayed onset, and better cognitive function despite brain pathology.

FDA Okays Pitolisant for Cataplexy in Pediatric Narcolepsy

With this new indication, pitolisant is now approved to treat excessive daytime sleepiness, cataplexy, or both, in patients aged 6 years or older with narcolepsy.

NeuroVoices: Katrina Bawden, MSN, MSCN, FNP-C, on Emerging Therapies and Women’s Health Priorities in Multiple Sclerosis Katrina Bawden, MSN, MSCN, FNP-C

A nurse practitioner at the Rocky Mountain MS Clinic discussed emerging therapeutics, evolving management strategies, and unmet needs in multiple sclerosis, specifically in women’s health.

FDA Accepts New Drug Application for Orexin Agonist Oveporexton in Narcolepsy Type 1, Grants Priority Review Isabella Ciccone, MPH

The FDA has granted priority review to Takeda’s new drug application for oveporexton, an orexin receptor 2-selective agonist, for narcolepsy type 1, with a PDUFA date in the third quarter of 2026.

NeurologyLive® Brain Games: February 8, 2026 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on diagnosing parasomnias!

Remelyinating Drug Bazedoxifene Fails to Meet End Points in Phase 2 Study of Multiple Sclerosis Louie Pasculli

Late-breaking data from the 2026 ACTRIMS Forum showed that bazedoxifene acetate failed to improve remyelination outcomes in midlife women with relapsing MS, despite a favorable safety profile.

Recommended News For You

Decrease seen in in situ breast cancer since 2009

More Data from Population-Based Studies Show CRC Screening Lowers Cancer Death Risk.

Stereotactic Radiation Linked to Better Brain Mets Outcomes

Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma

Obesity-related cancers are more likely in people who are obese in both healthy and unhealthy ways.

According to a study, patients with ovarian cancer who undergo aggressive surgery have a 70% lower chance of dying.

Novel Anti-CD38 Drug Shows Promise for Immune Thrombocytopenia

Recommended Articles For You

Revolutionizing Oncology: Pharmacometric Models in Personalized Cancer Drug Development 

Personalized Neoantigen Vaccines and the Promise of a Less Toxic Future in Pediatric Oncology 

Beyond the Battle: Navigating Life After Cancer 

Oncolytic Vaccinia Virus Immunotherapy: A New Frontier in GI Cancer Treatment 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version

2.

Ultrasound bras; HPV and thyroid cancer; language minimizing adverse events.

3.

Could semaglutide be used to treat addiction in addition to obesity?

4.

Neural networks and label-free microscopy enable accurate detection of pancreatic tumors

5.

Q&A: Odds of surviving cancer drop drastically when credit score dips

1.

Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer

2.

Mechanistic Depth and Clinical Impact of Rusfertide, Onyvide, IV Avastin, and Pemfexy

3.

AI Meets the Gut Microbiome: Early Detection of GI Malignancies Redefined

4.

What You Need To Know About Trametinib: A Miracle Cancer Treatment?

5.

Unlocking the Mystery of Leukemia: Exploring New Treatments and Hope for Patients

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

2.

Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment

3.

Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III

4.

Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion

5.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot